|Bid||64.25 x 800|
|Ask||67.80 x 800|
|Day's range||64.00 - 67.58|
|52-week range||29.27 - 84.31|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2023 - 24 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||63.39|
Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (CAGR) of 11.4% through 2032, reaching a $12.1 billion market by that time. Cancer is formed by changes to the genome in a body's cells, leading to uncontrollable growth.
To be sure, Coinbase still faces significant challenges. The company continues to post steep losses. Wood, though, remains bullish about the stock, and bought additional shares for the ARK Innovation ETF earlier this month.
Exact Sciences (EXAS) closed at $67.82 in the latest trading session, marking a -0.6% move from the prior day.